In the next part of our ongoing collaboration, the team at RoukenBio take a look at a key decision point early in the lifecycle of a potency assay: what cells to choose. Potency assays rely on cells as their foundation, acting as essential tools for measuring biological activity and ensuring therapeutic efficacy. The choice of cell substrate is crucial, as it directly impacts assay relevance, reproducibility, and overall performance. Selecting the right cell can be a complex process, particularly when starting from scratch, even despite the abundance of available resources and regulatory guidance.
We’ve teamed up with RoukenBio to create a blog series with a detailed focus on the key decisions along the road to a successful bioassay. RoukenBio are a leading immunology Contract Research Organisation (CRO) based in Motherwell, Scotland with a mission to facilitate breakthrough discoveries. Drawing on their immuno-oncology expertise, RoukenBio has built up an array of assay systems to recreate immune cell interactions in the tumour microenvironment, intended to be as faithful to the physiological processes they are emulating as possible. With a strong focus on novel and emerging therapeutic classes that are designed to modulate these processes, their assay platforms are applicable to oncology, auto-immunity, inflammatory disease and beyond.
Comments are closed.